Research Institute of Molecular Pathology IMP
Funded primarily by Boehringer Ingelheim and with unconstrained academic freedom, the Research Institute of Molecular Pathology (IMP) is a leading institute for biomedical researchin Vienna, Austria.
Search
Innovation in Oncology and Cancer Immunology Research
We are taking a diligent and broad approach, creating a collaborative research network to tap into a diversity of minds, which is vital in addressing some of the most challenging, but potentially most impactful, areas of cancer research.
Research Beyond Borders
Learn more about how our Research Beyond Borders team is uncovering new ideas and new science.
Data Science: Revolutionizing research and development with data driven insights
Using data in pharmaceutical research to better address patient needs
New cancer research building: Boosting innovation in oncology
With our new cancer research building in Vienna, we’ll advance our oncology pipeline and strengthen our commitment to innovation and collaboration.
Research at the Regional Center Vienna
The Regional Center Vienna counts for 33 countries and has been a central pillar in Boehringer Ingelheim’s global research network.
The Research Process
The Research Process
Research at Regional Center Vienna
RCV is the regional affiliate of Boehringer Ingelheim and responsible for over 30 countries in Central and Eastern Europe and Central Asia.
About Us
About Us
Boehringer Ingelheim’s Postdoctoral Program
Boehringer Ingelheim’s postdoctoral program in Regional Center Vienna (RCV) provides scientists with the opportunity to pursue research.
Our innovation strategy
Our Innovation Strategy at Boehringer Ingelheim in Research and Development
Biotherapeutics Discovery
Our committed team of scientists are using all their experience and knowledge to forge new research paths, engineer new molecules and do whatever it takes to make sure that no patient is left behind in our search for the next breakthrough.
Oncology Translational Science
Discover how Boehringer Ingelheim leverages translational science to bridge pre-clinical research and clinical development, enhancing patient outcomes in oncology. Learn about our patient-centric strategies, biomarker discovery, and collaborative efforts
“My ultimate goal is to cure cancer”
“My ultimate goal is to cure cancer”
Testing New Treatments for NF1
The Medical University of Vienna and Boehringer Ingelheim have taken an innovative approach to the development of ways of treating NF1-associated tumors.
Science Focus
Our Science Focus at Boehringer Ingelheim
COVID-19
Wir sehen es als unsere Pflicht an, bestmöglich für den Schutz und die Gesundheit unserer Mitarbeitenden, unserer Patienten und der Gesellschaft Sorge zu tragen. Um die globale Ausbreitung von COVID-19 einzudämmen und zu bewältigen, ist Boehringer Ingelhe
Retinal Diseases
At Boehringer Ingelheim, we have expanded our global research and development activities to tackle eye diseases, specifically those affecting the back of the eye.
Human Health
Human Health
Sites Around the World
Sites Around the World
Boehringer Ingelheim Awards Innovation Prize to Ablevia
Innovative solution from Ablevia for rapid and selective elimination of harmful antibodies without impediment to the immune system
Depression
Depression
Therapeutics
Therapeutics
Open Innovation Boehringer Ingelheim
Learn more about how we’re working across the innovation community to advance research and accelerate the development of new medicines
More Potential: Overview
Society continues to face challenges ranging from health to education, work prospects, living conditions, inequalities and poverty, often impacting vulnerable communities the most.